Dossier assessment
Cemiplimab (cutaneous squamous cell carcinoma, adjuvant) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Cemiplimab (cutaneous squamous cell carcinoma, CSCC) – Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Cemiplimab (cutaneous squamous cell carcinoma, CSCC) – Benefit assessment according to §35a Social Code Book V
Drug assessment at a glance
-
Drug assessment at a glance
Cemiplimab (cutaneous squamous cell carcinoma, adjuvant) – Benefit assessment according to §35a Social Code Book V
Dossier assessment
Adult patients with cutaneous squamous cell carcinoma at high risk of recurrence after surgery and radiation; adjuvant treatment
Added benefit not proven
Press releases
Cemiplimab for cutaneous squamous cell carcinoma: no suitable data due to the short duration of follow-up
Additional information
Federal Joint Committee (G-BA)
05-06-2026 A G-BA decision was published.
G-BA documents on this decision
Project details
- Project no.
- A25-155
- Commission
- Commission awarded on 15.12.2025 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
- DOI
https://doi.org/10.60584/A25-155_en
Connected Projects
-
Dossier assessment
Cemiplimab (cervical cancer) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Cemiplimab (NSCLC, combination with platin-based chemotherapy) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Cemiplimab (basal cell carcinoma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Cemiplimab (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Cemiplimab - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Addendum
Cemiplimab (cutaneous squamous cell carcinoma, adjuvant) – Addendum to Project A25-155
Status: Commission completed